Leprosy Review · 1971 · 64 citations · 14 references
PharmacyDermatologyPharmacotherapyImmunopharmacotherapyImmunotherapyRheumatologyCorticosteroid TherapyImmunosuppressionContinuous Course Of TreatmentDouble-blind TrialsPrednisolone UseSkin ErythemaThalidomide Analogs
A double-blind, internally-controlled, clinical trial of thalidpmide in severe, chronic, histologically-proven erythema nodosum leprosum (ENL) is reported. A total of 10 adult male patients were admitted to the trial, all of whom were receiving continuous treatment with steroids and whose minimum daily requirement just to suppress the reaction was in no case less than 15 mg of prednisolone or 18 international units of corticotrophin. The trial wa s divided into 4 equal parts (of either 4 or 6 weeks' duration) consisting of an initial control period, first and second trial periods, and a final control period. Throughout the trial all patients received DDS, 100 mg twice weekly ; thalidomide, 300 mg daily, wa s given during one trial period and identical placebo tablets during the other. As judged by the red uction in their steroid requirements, 9 of the 10 patients showed a very significant improvement while they were receiving thalidomide, although 7 subsequently relapsed after stopping the drug. There was no dose-for-dose relationship between thalidomide and prednisolone. Two patients developed a mild allergic dermatitis.
14
Classification of leprosy according to immunity. A five-group system.
D.S. Ridley, W. H. Jopling · PubMed · 1966 · 2.5K citations
Thalidomide in the treatment of lepra reactions
J Sheskin · Clinical Pharmacology & Therapeutics · 1965 · 533 citations
ERYTHEMA NODOSUM LEPROSUM: A CLINICAL MANIFESTATION OF THE ARTHUS PHENOMENON
S.N.C. Wemambu, J.L. Turk, Michael F. Waters et al. · The Lancet · 1969 · 306 citations
Medicine, Dermatology, Pathology +9
Neuropathy After Intake of Thalidomide (Distaval)
P. M. Fullerton, M. Kremer · BMJ · 1961 · 133 citations · Full text